Omada Health (OMDA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Reflections on public market journey

• Surpassed all IPO commitments, including financial, revenue, and margin targets, with Q1 revenue of $78 million and 43% growth, achieving profitability in the most cost-intensive quarter.

• Chronic disease care is shifting from episodic visits to continuous, technology-enabled support, reflected in strong business performance.

Business model and revenue durability

• Operates as a covered entity, filing claims on 10 unique codes, charging a monthly fee per engaged member, aligning incentives with customers.

• Revenue model supports consistent, durable growth, with quarter-by-quarter revenue increases and high customer alignment.

• Net dollar retention has always been above 100%, driven by ongoing enrollments and product expansion within existing accounts.

Clinical strategy and product expansion

• Invested heavily in clinical validation, with 30 peer-reviewed publications and industry-leading accreditations, including exclusive NCQA accreditation for diabetes and hypertension.

• Expanded from obesity prevention to diabetes, hypertension, cholesterol, and MSK care, driven by customer demand and clinical feasibility.

• About 50% of new customers adopt multiple products, with both diabetes and hypertension growing over 45% last year.